A quote for an API often lists a string of filings: US DMF, CEP, ASMF, sometimes a Japanese or Korean master file as well. They are not interchangeable, and they do not prove the same thing. This is what each one is, who has reviewed it, and how much weight it deserves in a US qualification.
US DMF: filed, not approved
A Type II US Drug Master File is the manufacturer’s confidential submission to FDA on how the drug substance is made and controlled. FDA does not approve it. The agency reviews the file only when an application references it, through a letter of authorization from the holder.
From the outside you can check two things: that the DMF is listed as active on FDA’s DMF list, and, for generic use, that it has passed the GDUFA completeness assessment and appears on the list of DMFs available for reference. A DMF number alone tells you a file exists. It does not tell you FDA has found the file adequate.
CEP: assessed and granted
A Certificate of Suitability to the monographs of the European Pharmacopoeia is issued by the EDQM, part of the Council of Europe. The manufacturer submits a dossier, EDQM assessors review it, and if their conclusion is positive the EDQM grants a certificate. It states that the Ph. Eur. monograph, together with any extra tests listed on the certificate, is suitable to control the quality of the substance made by that route at that site. The EDQM also runs its own inspection program.
So a CEP is a decision in a way a DMF is not: an authority has already reviewed the route and the impurity controls. It is also a document your supplier can show you. Read the annexes, which carry the additional tests, residual solvent limits and, where granted, the retest period.
ASMF: the European master file
Where a substance has no CEP, European applications can rely on an Active Substance Master File. It is split in two. The applicant’s part is shared with the customer, and the restricted part goes only to the authorities. Like a US DMF, an ASMF is assessed only as part of a marketing application and has no approval of its own. Unlike a US DMF, it gives you a formal open part to read.
Which one an ANDA needs
For a US ANDA, the filing that counts is the US DMF with a letter of authorization, or a complete drug substance section in your own application. FDA does not accept a CEP in its place.
A CEP still earns its place in a US qualification file, for three reasons:
- An independent authority has assessed the manufacturing route and how its impurities are controlled.
- The site falls under the EDQM’s inspection program, in addition to any FDA inspections.
- If the same product is later filed in Europe, or in other markets that recognize CEPs, the source is already covered.
What to ask for
- The US DMF number, holder and status, and whether it has passed the completeness assessment.
- A copy of the current CEP with its annexes, if one exists. Check the revision and the site named on it.
- Confirmation that the route and the site are the same across the filings. A manufacturer can hold a DMF for one process and a CEP for another.
- The letter of authorization for the DMF, arranged during qualification and not after the order.
- Evidence that the filings are kept current: DMF annual reports, and CEP revisions after changes.
Where Yog Pharma fits
Every quote lists the filings held for that source, with their numbers, so you can check them against FDA’s and the EDQM’s public databases before you ask for samples. The rest of the file is described on our quality page.